Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.


TSX:SVA - Post by User

Bullboard Posts
Comment by mjh9413on Sep 18, 2019 12:20am
125 Views
Post# 30138494

RE:News

RE:NewsI agree about  PR outlays but also have to add  while I don't see what their motives are, perhaps they 'see' meaningful progress is in their sights. As to padding their own pockets with the options, well, since we can all buy shares around 21c and padding pockets means the sp has to increase, well, we all have that op, except of course they do not put capital in upfront. 
Progress has been painstakingly slow but there has been progress on Diabates-1 front and I guess that this focus meant the Euro 225k they got in 2017 for the haemophilia side of things has simply got lost somewhere. Slow progress is the name of the game especially for this novel pouch idea and all that it entails. Still Diabetes-1 and Haemophilia are darn big markets and that, IMO, is the reason to remain invested in SVA.
Bullboard Posts